The Cohort Study of the Correlation Between Serum 25(OH)D Level and Pregnancy Outcome (NCT05824897) | Clinical Trial Compass
UnknownNot Applicable
The Cohort Study of the Correlation Between Serum 25(OH)D Level and Pregnancy Outcome
China171 participantsStarted 2022-11-01
Plain-language summary
The objective of this single-center prospective observational study is to clarify the trend of maternal serum 25(OH)D levels before pregnancy and during pregnancy, and to explore the correlation between serum 25(OH)D levels and subsequent pregnancy outcomes of patients with abortion, so as to provide certain scientific evidence for finding the optimal serum level of 25(OH)D and optimal vitamin D supplementation to maintain a healthy pregnancy.
Who can participate
Age range20 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* ≥20 years old
* The chromosome karyotype of the couple is normal
* Color ultrasound examination results indicated that there was no organic disease related to reproductive tract
* No serious complications of surgery and medicine
* Agree and voluntarily sign informed consent
Exclusion Criteria:
* There are contraindications to pregnancy
* the initiative to give up pregnancy
* Severe medical and surgical complications, for example, liver disease was defined as serum alanine aminotransferase \[ALT\] or aspartic aminotransferase \[AST\]\>3 x upper normal limit \[ULN\] after repeated testing
* Concomitant malignant tumor, malignant tumor developed in the last 5 years (except for the skin squamous basal cell carcinoma that has been removed and considered cured). Subjects who developed malignant tumors more than 5 years ago should provide evidence of remission or cure. Subjects with a history of cervical cancer were eligible if they could demonstrate that their cervical cancer had been cone removed or cured within the past 3 years
* Known human immunodeficiency virus (HIV) positive and/or hepatitis B surface antigen or hepatitis C virus antibody positive at screening visit
* With a history of chronic infections such as mycoplasma, chlamydia, cryptococcus, and invasive fungal infections should be discussed with the principal investigator